Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

With expertise in research, fundraising, policy and more, our staff are dedicated to making breakthroughs possible. Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined ...

Are you a dementia researcher or professional in the field? Don’t miss out on important updates about our upcoming dementia research events. Our 2026 Research Conference, will take place in Manchester ...

From posters to sponsorship forms, fundraising guides to sweepstakes, here are some handy resources you can download and use for your fundraising.

Looking for a challenge to test yourself, to get in shape, or bond with friends on a weekend adventure? If so, an Ultra Challenge® is for you – and you don’t need to be a budding elite athlete – ...

There are two main types of Alzheimer’s. Late onset Alzheimer’s starts after age 65, and young onset Alzheimer’s affects people before age 65. Different genes can be involved in the development of the ...

If you already have a place in this event but would like to support Alzheimer’s Research UK, we’d love to have you on the team! There’s no minimum sponsorship target and we can provide help and ...

For the majority of people, genes are only one of many factors that may increase their risk of getting dementia. Other factors that affect our dementia risk include our age, lifestyle and environment.